Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Burges

Showing results (41-50 of 118) with videos related to

Pageof 12
Sort By:
Clinical Chemistry and Laboratory Medicine|September 20, 2011
The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian massesMiriam Lenhard, Petra Stieber, Linda Hertlein, et al.
Virchows Archiv : an International Journal of Pathology|February 9, 2019
Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinomaElisa Schmoeckel, Sophie Hofmann, Daniel Fromberger, et al.
International Journal of Molecular Sciences|June 20, 2019
Correlation of the Aryl Hydrocarbon Receptor with FSHR in Ovarian Cancer PatientsEileen Deuster, Doris Mayr, Anna Hester, et al.
Zentralblatt Fur Chirurgie|September 18, 2025
[The Free Functional Latissimus dorsi Flap for the Reconstruction of Complex Abdominal Wall Defects: Anatomy, Technique and Approach for Interdisciplinary Treatment]Sinan Mert, Benedikt Fuchs, Alexander Burges, et al.
Brachytherapy|June 27, 2018
Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia: Clinical feasibility and initial resultsFranziska Walter, Cornelius Maihöfer, Lars Schüttrumpf, et al.
British Journal of Clinical Pharmacology|June 23, 2010
Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patientsPeter Ruf, Michael Kluge, Michael Jäger, et al.
Clinical Chemistry|March 4, 2008
A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF(110) in ovarian cancer tumorsJohnny Gutierrez, Gottfried E Konecny, Kyu Hong, et al.
Cancers|January 25, 2025
Necroptosis-Related Gene Signature Predicts Prognosis in Patients with Advanced Ovarian CancerMingjun Zheng, Mirjana Kessler, Udo Jeschke, et al.
Journal of Cancer Research and Clinical Oncology|September 6, 2019
EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancerBastian Czogalla, Christina Kuhn, Sabine Heublein, et al.
International Journal of Cancer|May 21, 2005
Immunotherapy of malignant ascites with trifunctional antibodiesMarkus M Heiss, Michael A Ströhlein, Michael Jäger, et al.
Pageof 12

Showing results (41-50 of 118) with videos related to

Sort By:
Pageof 12
Clinical Chemistry and Laboratory Medicine|September 20, 2011
The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian massesMiriam Lenhard, Petra Stieber, Linda Hertlein, et al.
Virchows Archiv : an International Journal of Pathology|February 9, 2019
Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinomaElisa Schmoeckel, Sophie Hofmann, Daniel Fromberger, et al.
International Journal of Molecular Sciences|June 20, 2019
Correlation of the Aryl Hydrocarbon Receptor with FSHR in Ovarian Cancer PatientsEileen Deuster, Doris Mayr, Anna Hester, et al.
Zentralblatt Fur Chirurgie|September 18, 2025
[The Free Functional Latissimus dorsi Flap for the Reconstruction of Complex Abdominal Wall Defects: Anatomy, Technique and Approach for Interdisciplinary Treatment]Sinan Mert, Benedikt Fuchs, Alexander Burges, et al.
Brachytherapy|June 27, 2018
Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia: Clinical feasibility and initial resultsFranziska Walter, Cornelius Maihöfer, Lars Schüttrumpf, et al.
British Journal of Clinical Pharmacology|June 23, 2010
Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patientsPeter Ruf, Michael Kluge, Michael Jäger, et al.
Clinical Chemistry|March 4, 2008
A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF(110) in ovarian cancer tumorsJohnny Gutierrez, Gottfried E Konecny, Kyu Hong, et al.
Cancers|January 25, 2025
Necroptosis-Related Gene Signature Predicts Prognosis in Patients with Advanced Ovarian CancerMingjun Zheng, Mirjana Kessler, Udo Jeschke, et al.
Journal of Cancer Research and Clinical Oncology|September 6, 2019
EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancerBastian Czogalla, Christina Kuhn, Sabine Heublein, et al.
International Journal of Cancer|May 21, 2005
Immunotherapy of malignant ascites with trifunctional antibodiesMarkus M Heiss, Michael A Ströhlein, Michael Jäger, et al.
Pageof 12